Fda approves libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with pd-l1 expression of ≥50%

Fda approves libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with pd-l1 expression of ≥50%
REGN Ratings Summary
REGN Quant Ranking